×
About 1,893 results

ALLMedicine™ Primary Biliary Cholangitis Center

Research & Reviews  627 results

Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and chall...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048470
World Journal of Gastroenterology; Pugliese N, Arcari I et. al.

May 19th, 2022 - Primary biliary cholangitis and primary sclerosing cholangitis (PSC) are the most common cholestatic liver diseases (CLD) in adults and are both characterized by an immune pathogenesis. While primary biliary cholangitis is a model autoimmune disea...

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
https://clinicaltrials.gov/ct2/show/NCT04950764

May 18th, 2022 - The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Pernicious Anemia Differential Diagnoses
https://emedicine.medscape.com/article/204930-differential

May 16th, 2022 - Diagnostic Considerations By definition, pernicious anemia refers specifically to vitamin B12 deficiency resulting from a lack of production of intrinsic factor (IF) in the stomach. However, vitamin B12 absorption is a complex process, and other c...

The intestinal and biliary microbiome in autoimmune liver disease-current evidence and ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088151
Seminars in Immunopathology; Liwinski T, Heinemann M et. al.

May 11th, 2022 - Autoimmune liver diseases are a group of immune-mediated liver diseases with three distinct entities, including autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. The interplay of genetic and environmental facto...

Hepatic Macrophage Types Cluster with Disease Etiology in Chronic Liver Disease and Dif...
https://doi.org/10.1177/10668969221099630
International Journal of Surgical Pathology; Zhang X, Thompkins-Johns A et. al.

May 7th, 2022 - Introduction. Macrophages are phenotypically heterogeneous cells that play a vital role in hepatic fibrogenesis. We aimed to compare the macrophage profiles between normal livers and those with various chronic liver diseases in the precirrhotic fi...

see more →

Guidelines  4 results

Non-invasive diagnosis and follow-up of primary biliary cholangitis.
https://doi.org/10.1016/j.clinre.2021.101770
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for t...
https://doi.org/10.1002/hep.30145
Hepatology (Baltimore, Md.); Lindor KD, Bowlus CL et. al.

Aug 3rd, 2018 - Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.|2018|Lindor KD,Bowlus CL,Boyer J,Levy C,Mayo M,|complications,diagnosis,therapy,

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment an...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109281
Gut Hirschfield GM, Dyson JK et. al.

Mar 30th, 2018 - Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an en...

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  26 results

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
https://clinicaltrials.gov/ct2/show/NCT04950764

May 18th, 2022 - The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
https://clinicaltrials.gov/ct2/show/NCT05050136

May 6th, 2022 - The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the diseas...

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
https://clinicaltrials.gov/ct2/show/NCT05292872

May 3rd, 2022 - This is an observational, retrospective cohort study of patients with primary biliary cholangitis (PBC) who failed ursodeoxycholic acid (UDCA) treatment, using a real-world data source, the Komodo Health United States (US) claims database. The stu...

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
https://clinicaltrials.gov/ct2/show/NCT03301506

May 2nd, 2022 - Primary: To evaluate the long-term safety and tolerability of seladelpar Secondary: To evaluate the long-term efficacy of seladelpar To evaluate the effect of seladelpar on patient-reported outcomes (pruritus)

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
https://clinicaltrials.gov/ct2/show/NCT04594694

Apr 27th, 2022 - Study to determine the effect of the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF) in patients with Primary Biliary Cholangitis (also known as PBC).

see more →

News  88 results

Immune-Mediated Diseases Tied to Risk of Cancer
https://www.medscape.com/viewarticle/964508

Dec 10th, 2021 - NEW YORK (Reuters Health) - Immune-mediated diseases were associated with an increased risk of local and systemic cancers, as well as total cancers, in a large cohort study, supporting the role of local and systemic immunoregulation in the develop...

FDA Restricts Obeticholic Acid (Ocaliva) Over Serious Liver Injury Risk
https://www.medscape.com/viewarticle/951931

May 26th, 2021 - The risk for serious liver injury with obeticholic acid (Ocaliva, Intercept Pharmaceuticals) has prompted the US Food and Drug Administration (FDA) to restrict its use in patients with primary biliary cholangitis (PBC) and advanced cirrhosis.  The...

Incidence of Autoimmune Hepatitis May Be Rising
https://www.medscape.com/viewarticle/945131

Feb 2nd, 2021 - The incidence of autoimmune hepatitis (AIH) may be rising, according to a prospective population-based study conducted in New Zealand. From 2008 to 2016, the rising incidence of AIH led to a 40% increase in point prevalence, reported lead author M...

Incidence of autoimmune hepatitis may be rising
https://www.mdedge.com/internalmedicine/article/235224/gastroenterology/incidence-autoimmune-hepatitis-may-be-rising
Will Pass

Jan 29th, 2021 - The incidence of autoimmune hepatitis (AIH) may be rising, according to a prospective population-based study conducted in New Zealand. From 2008 to 2016, the rising incidence of AIH led to a 40% increase in point prevalence, reported lead author M.

Bezafibrate eased pruritus in patients with fibrosing cholangiopathies
https://www.mdedge.com/internalmedicine/article/234323/gastroenterology/bezafibrate-eased-pruritus-patients-fibrosing
Amy Karon

Jan 7th, 2021 - Once-daily treatment with the lipid-lowering agent bezafibrate significantly reduced moderate to severe pruritis among patients with cholestasis, according to the findings of a multicenter, double-blind, randomized, placebo-controlled study (Fibra.

see more →

Patient Education  6 results see all →